AML Matters Summit, ASH President Participates in LLS Panel Discussion, and more

AML Matters Summit Continues Across U.S.

AML Matters is a free educational program designed to provide guidance to health-care professionals on the optimal diagnosis and classification of acute myeloid leukemia, risk stratification, individualized treatment selection, assessment of treatment responses, monitoring for and mitigation of adverse events, and patient education regarding prognosis and treatment choices. This program is sponsored by the American Society of Hematology, American Society for Clinical Pathology, National Marrow Donor Program, Oncology Nursing Society, and The France Foundation.

Upcoming dates and locations include:

  • Minneapolis, MN (July 28, 2017)
  • Durham, NC (October 20, 2017)
  • Philadelphia, PA (October 27, 2017)

ASH President Participates in LLS Panel Discussion

American Society of Hematology (ASH) President Kenneth Anderson, MD, participated in an event organized by The Leukemia & Lymphoma Society (LLS) with other leading experts on blood cancers and health-care policy in

Washington, DC, in early May to discuss the rising cost of cancer care, as well as advances in precision medicine and immunotherapy. In conjunction with the event, LLS issued its Report to the Nation: Leading the Way to Cancer Cures, a comprehensive overview of the major scientific, treatment, and policy advances of the last six decades that have affected patients with blood cancer.

The panel discussion, titled, “Precision Medicine: Pursuing Novel Targeted Therapies and Immunotherapies to Fight Cancer,” featuring leukemia, lymphoma, and myeloma researchers and clinicians, discussed the potential of new scientific discoveries to change the model of cancer treatment.

“Of course we’re going to cure cancer,” said Dr. Anderson. “There’s not even any question. The way it’s going to be done is by a team.”

Source: Leukemia & Lymphoma Society news release, May 3, 2017.


Plan Ahead for ASH Meeting on Lymphoma Biology

It’s not too soon to mark your calendar for the next ASH Meeting on Lymphoma Biology, taking place August 2-5, 2018, just outside Washington, DC. This 4-day meeting offers a platform for the latest developments in lymphoma science, identifying challenges and establishing the highest priorities for investigation. The target audience for this meeting includes laboratory-based scientists, translational investigators, pharmaceutical scientists, and others interested in lymphoma science. For more information, visit hematology.org/Lymphoma-Biology.


Webinar Preview of the 2017 ASH Meeting on Hematologic Malignancies

A special webinar series previewing the 2017 ASH Meeting on Hematologic Malignancies is available for free streaming from ASH On Demand at ashondemand.org/Webinars. If you’re considering attending the meeting, watch this series to get a sense of the content that will be covered in person, September 8-9 in Chicago, Illinois. The meeting will feature top experts in the field, comprehensive clinical updates, the latest clinical research, and opportunities to interact with colleagues in a small-group setting. The core malignancies covered at the meeting include leukemia, lymphoma, myelodysplastic syndromes, myeloma, and myeloproliferative neoplasms. For information visit hematology.org/Malignancies.

The most recent webinar took place in May and featured a discussion on the state of myeloproliferative neoplasms with Ruben Mesa, MD, Mayo Clinic, Phoenix, Arizona, and Jason Gotlib, MD, Stanford University, California.

SHARE